Kindred Biosciences (NASDAQ:KIN) received a $11.00 price target from equities researchers at B. Riley in a research note issued to investors on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s price target suggests a potential upside of 46.67% from the company’s previous close.

A number of other analysts have also recently weighed in on the company. Zacks Investment Research cut Kindred Biosciences from a “buy” rating to a “hold” rating and set a $8.50 price target on the stock. in a research report on Tuesday, September 12th. HC Wainwright began coverage on Kindred Biosciences in a research report on Friday, November 17th. They set a “buy” rating and a $9.50 price target on the stock. Finally, ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $9.63.

Shares of Kindred Biosciences (KIN) opened at $7.50 on Tuesday. Kindred Biosciences has a one year low of $4.10 and a one year high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. equities analysts expect that Kindred Biosciences will post -1.18 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of KIN. General American Investors Co. Inc. acquired a new stake in Kindred Biosciences in the 3rd quarter valued at approximately $5,232,000. AJO LP bought a new position in Kindred Biosciences during the 2nd quarter valued at $2,407,000. Vanguard Group Inc. boosted its stake in Kindred Biosciences by 57.7% during the 2nd quarter. Vanguard Group Inc. now owns 745,322 shares of the biopharmaceutical company’s stock valued at $6,410,000 after purchasing an additional 272,612 shares in the last quarter. State Street Corp bought a new position in Kindred Biosciences during the 2nd quarter valued at $2,209,000. Finally, Pacific Grove Capital LP bought a new position in Kindred Biosciences during the 3rd quarter valued at $1,475,000. Hedge funds and other institutional investors own 66.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Kindred Biosciences (KIN) Given a $11.00 Price Target by B. Riley Analysts” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/07/kindred-biosciences-kin-given-a-11-00-price-target-by-b-riley-analysts.html.

About Kindred Biosciences

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.